Two-year Update From CheckMate 141: Outcomes With Nivolumab (Nivo) vs Investigator's Choice (IC) in Recurrent or Metastatic (R/M) Squamous Cell Carcinoma of the Head and Neck (SCCHN) in the Overall Population and PD-L1 Subgroups

著录项

• 来源
  《International Journal of Radiation Oncology, Biology, Physics》 |2018年第5期|共1页
• 作者

  Ferris R. L.; Blumenschein G. R.; Fayette J.; Guigay J.; Colevas A. D.; Licitra L.; Harrington K.; Kasper S.; Vokes E. E.; Even C.; Worden F.; Saba N. F.; Docampo LCIglesias; Haddad R. I.; Rordorf T.; Kiyota N.; Tahara M.; Lynch M.; Li L.; Gillison M.;

  展开▼
• 作者单位

  UPMC Hillman Canc Ctr Pittsburgh PA USA;

  Univ Texas MD Anderson Canc Ctr Houston TX 77030 USA;

  Ctr Leon Berard Lyon France;

  FHU OncoAge Ctr Antoine Lacassagne Nice France;

  Stanford Univ Stanford CA 94305 USA;

  Fdn IRCCS Ist Nazl Tumori Milan Italy;

  Royal Marsden NHS Fdn Trust Inst Canc Res London England;

  Univ Hosp Essen West German Canc Ctr Essen Germany;

  Univ Chicago Med Ctr Chicago IL 60637 USA;

  Gustave Roussy Villejuif France;

  Univ Michigan Ann Arbor MI 48109 USA;

  Emory Univ Winship Canc Inst Atlanta GA 30322 USA;

  Hosp Univ 12 Octubre Madrid Spain;

  Dana Farber Harvard Canc Ctr Boston MA USA;

  Univ Spital Zurich Zurich Switzerland;

  Kobe Univ Hosp Kobe Hyogo Japan;

  Natl Canc Ctr Hosp East Kashiwa Chiba Japan;

  Bristol Myers Squibb Princeton NJ USA;

  Bristol Myers Squibb Princeton NJ USA;

  展开▼
• 收录信息
• 原文格式 PDF
• 正文语种 eng
• 中图分类 放射医学;
• 关键词